Keywords
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Keywords » - entrée « Antirheumatic Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antirheumatic Agents (administration & dosage) < Antirheumatic Agents (adverse effects) < Antirheumatic Agents (blood)  Facettes :

List of bibliographic references indexed by Antirheumatic Agents (adverse effects)

Number of relevant bibliographic references: 317.
[20-40] [0 - 20][0 - 50][40-60]
Ident.Authors (with country if any)Title
000B44 (2019) Navita L. Mallalieu [États-Unis] ; Sunethra Wimalasundera [Royaume-Uni] ; Joy C. Hsu [États-Unis] ; Wendy Douglass [Royaume-Uni] ; Chris Wells [Royaume-Uni] ; Inmaculada Calvo Penades [Espagne] ; Ruben Cuttica [Argentine] ; Hans-Iko Huppertz [Allemagne] ; Rik Joos [Belgique] ; Yukiko Kimura [États-Unis] ; Diana Milojevic [États-Unis] ; Margalit Rosenkranz [États-Unis] ; Kenneth Schikler [États-Unis] ; Tamas Constantin [Hongrie] ; Carine Wouters [Belgique]Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
000B83 (2019) Toshiyuki Watanabe [Japon] ; Jun Fukae [Japon] ; Shinji Fukaya [Japon] ; Norifumi Sawamukai [Japon] ; Masato Isobe [Japon] ; Megumi Matsuhashi [Japon] ; Masato Shimizu [Japon] ; Kazumasa Akikawa [Japon] ; Kazuhide Tanimura [Japon] ; Tatsuya Atsumi [Japon] ; Takao Koike [Japon]Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
000C23 (2019) Atsushi Ogata [Japon] ; Yasuhiro Kato [Japon] ; Shinji Higa [Japon] ; Kazuyuki Yoshizaki [Japon]IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
000C93 (2019) Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France]Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
000D20 (2019) Han Joo Baek [Corée du Sud] ; Mie Jin Lim [Corée du Sud] ; Won Park [Corée du Sud] ; Sung Hwan Park [Corée du Sud] ; Seung-Cheol Shim [Corée du Sud] ; Dae-Hyun Yoo [Corée du Sud] ; Hyun Ah Kim [Corée du Sud] ; Soo Kon Lee [Corée du Sud] ; Yun Jong Lee [Corée du Sud] ; Young Eun Park [Corée du Sud] ; Hoon-Suk Cha [Corée du Sud] ; Yeong-Wook Song [Corée du Sud]Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
000D47 (2019) Izumi Kurata [Japon] ; Hiroto Tsuboi [Japon] ; Mayu Terasaki [Japon] ; Masaru Shimizu [Japon] ; Hirofumi Toko [Japon] ; Fumika Honda [Japon] ; Ayako Ohyama [Japon] ; Mizuki Yagishita [Japon] ; Atsumu Osada [Japon] ; Hiroshi Ebe [Japon] ; Hoshimi Kawaguchi [Japon] ; Hiroyuki Takahashi [Japon] ; Shinya Hagiwara [Japon] ; Hiromitsu Asashima [Japon] ; Yuya Kondo [Japon] ; Isao Matsumoto [Japon] ; Takayuki Sumida [Japon]Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
000D54 (2019) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
000E39 (2019) C. Diener [Allemagne] ; G. Horneff [Allemagne]Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
000E42 (2019) Katsuhiko Takabayashi [Japon] ; Fumihiko Ando [États-Unis] ; Takahiro Suzuki [Japon]Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data.
000E47 (2019) Jacques-Eric Gottenberg [France] ; Jacques Morel [France] ; Elodie Perrodeau [France] ; Thomas Bardin [France] ; Bernard Combe [France] ; Maxime Dougados [France] ; Rene-Marc Flipo [France] ; Alain Saraux [France] ; Thierry Schaeverbeke [France] ; Jean Sibilia [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Gabriel Baron [France] ; Arnaud Constantin [France] ; Philippe Ravaud [France] ; Xavier Mariette [France]Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
001089 (2018) Chia-Hua Lin [Taïwan] ; Hsiang-Cheng Chen [Taïwan] ; Hong-Wei Gao [Taïwan] ; Bai-Yao Wu [Taïwan]Wolf's post-herpetic isotopic response to tocilizumab for rheumatoid arthritis.
001119 (2018) Hitoshi Imamura [Japon] ; Shigeki Momohara [Japon] ; Koichiro Yano [Japon] ; Yu Sakuma [Japon] ; Masanori Nakayama [Japon] ; Haruki Tobimatsu [Japon] ; Katsunori Ikari [Japon]Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty.
001141 (2018) Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
001150 (2018) Maria Gerosa [Italie] ; Lorenza Maria Argolini [Italie] ; Carolina Artusi [Italie] ; Cecilia Beatrice Chighizola [Italie]The use of biologics and small molecules in pregnant patients with rheumatic diseases.
001205 (2018) Jean-Hugues Salmon ; Jeanne-Marie Perotin ; Jacques Morel [France] ; Moustapha Dramé ; Alain Cantagrel [France] ; Liana Euller Ziegler ; Philippe Ravaud [France] ; Jean Sibilia ; Isabelle Pane [France] ; Xavier Mariette ; Jacques-Eric Gottenberg [France]Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
001206 (2018) Andrew I. Rutherford [Royaume-Uni] ; Sujith Subesinghe [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni] ; James B. Galloway [Royaume-Uni]Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
001212 (2018) Sung Soo Ahn [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Jason Jungsik Song [Corée du Sud] ; Yong Beom Park [Corée du Sud] ; Jun Yong Park [Corée du Sud] ; Sang Won Lee [Corée du Sud]Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
001213 (2018) Tatsuya Atsumi [Japon] ; Keishi Fujio [Japon] ; Kunihiro Yamaoka [Japon] ; Minako Tomobe [Japon] ; Kazuyuki Kuroyanagi [Japon] ; Hideto Kameda [Japon]Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
001216 (2018) Sen Wang [République populaire de Chine] ; Qian He [République populaire de Chine] ; Zongwen Shuai [République populaire de Chine]Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
001218 (2018) I. Serio [Italie] ; F. Tovoli [Italie]Rheumatoid arthritis: new monoclonal antibodies.
001222 (2018) Jacqueline Bullock [États-Unis] ; Syed A A. Rizvi [États-Unis] ; Ayman M. Saleh [Oman] ; Sultan S. Ahmed [États-Unis] ; Duc P. Do [États-Unis] ; Rais A. Ansari [États-Unis] ; Jasmin Ahmed [États-Unis]Rheumatoid Arthritis: A Brief Overview of the Treatment.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antirheumatic Agents (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antirheumatic Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antirheumatic Agents (adverse effects)
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021